Replies to post #2646 on RedHill Biopharma Ltd (RDHL)

[midastouch017]

As the headline mentioned, the results
were positive, albeit too small a sample.
Hopefully good news from the

The efficacy
of opaganib in severe COVID-19 pneumonia is being
further explored in an ongoing global Phase 2/3
study and is expected to report top-line data in
the first quarter of 2021. This study (NCT04467840)
is being conducted across approximately 30 clinical
sites in several countries and is on track to enroll
up to 270 patients. The study has undergone two
unblinded reviews of safety data by an independent
Data and Safety Monitoring Board (DSMB), with unanimous
recommendations to continue the study. An interim DSMB
futility analysis will be conducted in the coming weeks,
evaluating data from the first 135 subjects that have
reached the primary endpoint.

Overall i am optimistic although i am not too happy
the way the stock is priced.